Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery
Lindemann H, Kuehne M, Grune C, Warncke P, Hofmann S, Koschella A, Godmann M, Fischer D, Heinzel T, Heinze T (2020)
Publication Type: Journal article
Publication year: 2020
Journal
Book Volume: 20
Article Number: 2000039
Journal Issue: 6
Abstract
The histone deacetylase inhibitors (HDACi) are potent drugs in the treatment of inflammatory diseases and defined cancer types. However, major drawbacks of HDACi, such as valproic acid (VPA), are limited serum half-life, side effects and the short circulation time. Thus, the immobilization of VPA in a polysaccharide matrix is used to circumvent these problems and to design a suitable nanocarrier system. Therefore, VPA is covalently attached to cellulose and dextran via esterification with degree of substitution (DS) values of up to 2.20. The resulting hydrophobic polymers are shaped to spherical nanoparticles (NPs) with hydrodynamic diameter between 138 to 221 nm and polydispersity indices from 0.064 to 0.094 by nanoprecipitation and emulsification technique. Lipase treatment of the NPs leads to in vitro release of VPA and hence to an inhibition of HDAC2 activity in a HDAC2 assay. NPs are rapidly taken up by HeLa cells and mainly localize in the cytoplasm. The NPs are hemocompatible and nontoxic as revealed by the shell-less hen’s egg model.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Lindemann, H., Kuehne, M., Grune, C., Warncke, P., Hofmann, S., Koschella, A.,... Heinze, T. (2020). Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery. Macromolecular Bioscience, 20(6). https://dx.doi.org/10.1002/mabi.202000039
MLA:
Lindemann, Henry, et al. "Polysaccharide Nanoparticles Bearing HDAC Inhibitor as Nontoxic Nanocarrier for Drug Delivery." Macromolecular Bioscience 20.6 (2020).
BibTeX: Download